Business
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
LANGHORNE, Pa., May 11, 2026--Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on Tuesday, May 19th at 10:00am ET in New York, NY at the NASDAQ headquarters.
About this update from Savara, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/e5982b0792071bf8129c05aa781f5f0c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tmJ_WJBuFymHuhluOAV7yA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/e5982b0792071bf8129c05aa781f5f0c","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/NqZkylBX4.JmjJtBsFpVOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/e5982b0792071bf8129c05aa781f5f0c","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5F9ZK1qwUir.qesPmHavdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/e5982b0792071bf8129c05aa781f5f0c","width":1024,"height":512}},"lazy":false},{"type":"text","content":"LANGHORNE, Pa., May 11, 2026--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on Tuesday, May 19th at 10:00am ET in New York, NY at the NASDAQ headquarters.","length":423,"tagName":"p"},{"type":"text","content":"The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company’s corporate website and will be archived for 90 days.","length":179,"tagName":"p"},{"type":"text","content":"About Savara","length":12,"tagName":"p"},{"type":"text","content":"Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercializa...